(Q36716433)

15 August 2017

1 reference

title

Mechanisms of disease: HDL metabolism as a target for novel therapies (English)

1 reference

15 August 2017

Daniel J Rader

1

1 reference

15 August 2017

publication date

1 February 2007

1 reference

Nature Clinical Practice Cardiovascular Medicine

15 August 2017

published in

1 reference

15 August 2017

volume

4

1 reference

15 August 2017

issue

2

1 reference

15 August 2017

page(s)

102-109

1 reference

Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0768

7 January 2021

Intensive versus moderate lipid lowering with statins after acute coronary syndromes

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0768

7 January 2021

Intensive lipid lowering with atorvastatin in patients with stable coronary disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0768

7 January 2021

Clinical practice. Low HDL cholesterol levels

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0768

7 January 2021

New insights into the regulation of HDL metabolism and reverse cholesterol transport

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0768

7 January 2021

Targeted inactivation of hepatic Abca1 causes profound hypoalphalipoproteinemia and kidney hypercatabolism of apoA-I

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0768

7 January 2021

Intestinal ABCA1 directly contributes to HDL biogenesis in vivo

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0768

7 January 2021

ABC1: connecting yellow tonsils, neuropathy, and very low HDL.

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0768

7 January 2021

ATP-binding cassette transporters G1 and G4 mediate cellular cholesterol efflux to high-density lipoproteins

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0768

7 January 2021

ABCG1 has a critical role in mediating cholesterol efflux to HDL and preventing cellular lipid accumulation

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0768

7 January 2021

PPAR- and LXR-dependent pathways controlling lipid metabolism and the development of atherosclerosis

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0768

7 January 2021

Scavenger receptor class B type I as a mediator of cellular cholesterol efflux to lipoproteins and phospholipid acceptors

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0768

7 January 2021

Hepatic expression of scavenger receptor class B type I (SR-BI) is a positive regulator of macrophage reverse cholesterol transport in vivo

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0768

7 January 2021

Lipoprotein cholesteryl ester production, transfer, and output in vivo in humans

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0768

7 January 2021

Antiinflammatory properties of HDL.

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0768

7 January 2021

Increased atherosclerosis in mice lacking apolipoprotein A-I attributable to both impaired reverse cholesterol transport and increased inflammation

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0768

7 January 2021

Inflammatory/antiinflammatory properties of high-density lipoprotein distinguish patients from control subjects better than high-density lipoprotein cholesterol levels and are favorably affected by simvastatin treatment

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0768

7 January 2021

Endothelial and antithrombotic actions of HDL.

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0768

7 January 2021

Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0768

7 January 2021

Nicotinic acid in the management of dyslipidaemia associated with diabetes and metabolic syndrome: a position paper developed by a European Consensus Panel

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0768

7 January 2021

Nicotinic acid: the broad-spectrum lipid drug. A 50th anniversary review

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0768

7 January 2021

Molecular basis of lipid transfer protein deficiency in a family with increased high-density lipoproteins

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0768

7 January 2021

Increased high-density lipoprotein levels caused by a common cholesteryl-ester transfer protein gene mutation

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0768

7 January 2021

Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0768

7 January 2021

A review of CETP and its relation to atherosclerosis

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0768

7 January 2021

Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans: a randomized phase II dose-response study

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0768

7 January 2021

Effectiveness of inhibition of cholesteryl ester transfer protein by JTT-705 in combination with pravastatin in type II dyslipidemia

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0768

7 January 2021

Raising high-density lipoprotein in humans through inhibition of cholesteryl ester transfer protein: an initial multidose study of torcetrapib

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0768

7 January 2021

Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0768

7 January 2021

Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0768

7 January 2021

Torcetrapib/atorvastatin combination therapy

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0768

7 January 2021

Delayed catabolism of high density lipoprotein apolipoproteins A-I and A-II in human cholesteryl ester transfer protein deficiency

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0768

7 January 2021

Increased catabolic rate of low density lipoproteins in humans with cholesteryl ester transfer protein deficiency

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0768

7 January 2021

Effects of cholesteryl ester transfer protein inhibition on high-density lipoprotein subspecies, apolipoprotein A-I metabolism, and fecal sterol excretion.

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0768

7 January 2021

Effects of the cholesteryl ester transfer protein inhibitor torcetrapib on apolipoprotein B100 metabolism in humans

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0768

7 January 2021

Effect of inhibiting cholesteryl ester transfer protein on the kinetics of high-density lipoprotein cholesteryl ester transport in plasma: in vivo studies in rabbits.

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0768

7 January 2021

Large and cholesteryl ester-rich high-density lipoproteins in cholesteryl ester transfer protein (CETP) deficiency can not protect macrophages from cholesterol accumulation induced by acetylated low-density lipoproteins

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0768

7 January 2021

HDL from CETP-deficient subjects shows enhanced ability to promote cholesterol efflux from macrophages in an apoE- and ABCG1-dependent pathway

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0768

7 January 2021

Inhibition of cholesteryl ester transfer protein activity: a new therapeutic approach to raising high-density lipoprotein

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0768

7 January 2021

Genetic cholesteryl ester transfer protein deficiency is extremely frequent in the Omagari area of Japan. Marked hyperalphalipoproteinemia caused by CETP gene mutation is not associated with longevity

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0768

7 January 2021

Atherosclerotic disease in marked hyperalphalipoproteinemia. Combined reduction of cholesteryl ester transfer protein and hepatic triglyceride lipase

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0768

7 January 2021

Frequency of exon 15 missense mutation (442D:G) in cholesteryl ester transfer protein gene in hyperalphalipoproteinemic Japanese subjects

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0768

7 January 2021

A Low Prevalence of Coronary Heart Disease among Subjects with Increased High-Density Lipoprotein Cholesterol Levels, Including Those with Plasma Cholesteryl Ester Transfer Protein Deficiency

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0768

7 January 2021

A prospective study of HDL-C and cholesteryl ester transfer protein gene mutations and the risk of coronary heart disease in the elderly

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0768

7 January 2021

Natural genetic variation as a tool in understanding the role of CETP in lipid levels and disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0768

7 January 2021

Cholesteryl ester transfer protein TaqIB variant, high-density lipoprotein cholesterol levels, cardiovascular risk, and efficacy of pravastatin treatment: individual patient meta-analysis of 13,677 subjects.

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0768

7 January 2021

Plasma levels of cholesteryl ester transfer protein and the risk of future coronary artery disease in apparently healthy men and women: the prospective EPIC (European Prospective Investigation into Cancer and nutrition)-Norfolk population study

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0768

7 January 2021

The ATP binding cassette transporter A1 (ABCA1) modulates the development of aortic atherosclerosis in C57BL/6 and apoE-knockout mice

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0768

7 January 2021

HDL as a target in the treatment of atherosclerotic cardiovascular disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0768

7 January 2021

Pharmacological activation of liver X receptors promotes reverse cholesterol transport in vivo

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0768

7 January 2021

Synthetic LXR ligand inhibits the development of atherosclerosis in mice

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0768

7 January 2021

Macrophage liver X receptor is required for antiatherogenic activity of LXR agonists

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0768

7 January 2021

Synthetic LXR agonists increase LDL in CETP species

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0768

7 January 2021

PPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0768

7 January 2021

Differential inhibition of macrophage foam-cell formation and atherosclerosis in mice by PPARalpha, beta/delta, and gamma

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0768

7 January 2021

Effects of pioglitazone on lipoproteins, inflammatory markers, and adipokines in nondiabetic patients with metabolic syndrome

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0768

7 January 2021

A selective peroxisome proliferator-activated receptor delta agonist promotes reverse cholesterol transport

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0768

7 January 2021

Triglyceride:high-density lipoprotein cholesterol effects in healthy subjects administered a peroxisome proliferator activated receptor delta agonist.

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0768

7 January 2021

PUMA-G and HM74 are receptors for nicotinic acid and mediate its anti-lipolytic effect

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0768

7 January 2021

Flushing out the role of GPR109A (HM74A) in the clinical efficacy of nicotinic acid

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0768

7 January 2021

GPR109A (PUMA-G/HM74A) mediates nicotinic acid-induced flushing

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0768

7 January 2021

Antagonism of the prostaglandin D2 receptor 1 suppresses nicotinic acid-induced vasodilation in mice and humans

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0768

7 January 2021

Rimonabant: a cannabinoid receptor blocker for the treatment of metabolic and cardiovascular risk factors

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0768

7 January 2021

Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0768

7 January 2021

Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0768

7 January 2021

Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0768

7 January 2021

The unfolding cannabinoid story on energy homeostasis: central or peripheral site of action?

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0768

7 January 2021

Cardiovascular risk management by blocking the endocannabinoid system

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0768

7 January 2021

Rimonabant: a selective blocker of the cannabinoid CB1 receptors for the management of obesity, smoking cessation and cardiometabolic risk factors

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0768

7 January 2021

Human apolipoprotein A-I gene expression increases high density lipoprotein and suppresses atherosclerosis in the apolipoprotein E-deficient mouse

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0768

7 January 2021

Regression of atherosclerosis induced by liver-directed gene transfer of apolipoprotein A-I in mice

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0768

7 January 2021

Overexpression of apolipoprotein A-I promotes reverse transport of cholesterol from macrophages to feces in vivo

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0768

7 January 2021

Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0768

7 January 2021

High-density lipoproteins as an emerging therapeutic target for atherosclerosis

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0768

7 January 2021

Apolipoprotein A-I mimetic peptides

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0768

7 January 2021

Oral administration of an Apo A-I mimetic Peptide synthesized from D-amino acids dramatically reduces atherosclerosis in mice independent of plasma cholesterol

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0768

7 January 2021

Oral D-4F causes formation of pre-beta high-density lipoprotein and improves high-density lipoprotein-mediated cholesterol efflux and reverse cholesterol transport from macrophages in apolipoprotein E-null mice

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0768

7 January 2021

Atheroprotective effects of high-density lipoprotein-associated lysosphingolipids

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0768

7 January 2021

Immunomodulator FTY720 Induces eNOS-dependent arterial vasodilatation via the lysophospholipid receptor S1P3.

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0768

7 January 2021

Identifiers

DOI

10.1038/NCPCARDIO0768

1 reference

15 August 2017

1 reference